Cingulate, Inc. (CING)
5.33
+0.14
(+2.70%)
USD |
NASDAQ |
Sep 09, 11:41
Cingulate Net Income (Quarterly) : -5.870M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.870M |
| March 31, 2026 | -9.312M |
| December 31, 2025 | -6.273M |
| September 30, 2025 | -7.341M |
| June 30, 2025 | -4.983M |
| March 31, 2025 | -3.853M |
| December 31, 2024 | -6.231M |
| September 30, 2024 | -4.126M |
| June 30, 2024 | -3.210M |
| March 31, 2024 | -2.972M |
| Date | Value |
|---|---|
| December 31, 2023 | -6.935M |
| September 30, 2023 | -5.979M |
| June 30, 2023 | -6.616M |
| March 31, 2023 | -4.005M |
| December 31, 2022 | -4.605M |
| September 30, 2022 | -4.027M |
| June 30, 2022 | -4.040M |
| March 31, 2022 | -5.004M |
| June 30, 2021 | -1.432M |
| March 31, 2021 | -1.334M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 5.534B |
| Eli Lilly & Co. | 7.095B |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.870M |
| EPS Diluted (Quarterly) | -0.4452 |
| Enterprise Value | 50.00M |
| Earnings Yield | -67.84% |
| Normalized Earnings Yield | -63.86 |